Comparative Evaluation of Short-term Clinical Safety and Efficacy of COVID-19 Vaccines - Covishield and Covaxin

Arunkumar Radhakrishnan; Abinaya Elango; Maignana Kumar Rajamanickam; Ruckmani Arunachalam

Arunkumar Radhakrishnan Professor, Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Chengalpattu (Dt), Tamil Nadu, India.
Abinaya Elango Assistant Professor, Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Chengalpattu (Dt), Tamil Nadu, India.
Maignana Kumar Rajamanickam Associate Professor, Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Chengalpattu (Dt), Tamil Nadu, India.
Ruckmani Arunachalam Professor, Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Chengalpattu (Dt), Tamil Nadu, India.

Keywords: COVID-19, Covishield, Covaxin, Safety, Efficacy

Abstract

Background: Many candidate vaccines against COVID-19 are competing for their clinical safety and efficacy but few have got approval from the competent authorities. However, people are still concerned about their use.

Objectives: To assess the clinical safety of COVID-19 vaccines, Covishield and Covaxin using the incidence of self-reported and solicited local and systemic adverse events and efficacy by collecting data on the occurrence of confirmed COVID-19 infection after vaccination and to compare the clinical safety and efficacy of both the vaccines.

Method: This study was conducted as an online survey using a self-administered questionnaire, among the individuals who were vaccinated in the months of February, March and April 2021. The participants were categorised into two groups, based on the type of vaccine they received as Covishield and Covaxin. The two groups did not differ in terms of age and gender.

Results: The proportion of participants who had adverse events after the first dose of vaccination was significantly high with Covishield (37.2%) compared to Covaxin (17.4%). But the proportion of participants who developed adverse events after the second dose was not significantly different between Covishield and Covaxin (16.1% with Covishield and 23.8% with Covaxin). The incidence of COVID-19 infection after vaccination was similar in both the groups (4.5% in Covishield group and 5.7% in Covaxin group, p = 0.5, Chi-square test).

Conclusion: The findings from this study gives real-world data that both Covishield and Covaxin are equally effective in preventing COVID-19 infection and have an acceptable safety profile.

How to cite this article:
Radhakrishnan A, Elango A, Rajamanickam MK, Arunachalam R. Comparative Evaluation of Shortterm
Clinical Safety and Efficacy of COVID-19 Vaccines - Covishield and Covaxin. Special Issue - COVID-19 & Other Communicable Disease. 2022;41-48.

DOI: https://doi.org/10.24321/0019.5138.202207

References

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni Vk, Kanungo S, Rai S, Reddy P, Verma S. Efficacy, Safety, And Lot To Lot Immunogenicity Of An Inactivated Sars-Cov-2 Vaccine (Bbv152): A Double-Blind, Randomised, Controlled Phase 3 Trial. Lancet. 2021 Dec;398(10317):2173-84. [Pubmed] [Google Scholar]

Voysey M, Clemens Sac, Madhi Sa, Weckx Ly, Folegatti Pm, Aley Pk, Angus B, Baillie Vl, Barnabas Sl, Bhorat Qe, Bibi S, Briner C, Cicconi P, Collins Am, Colin-Jones R, Cutland Cl, Darton Tc, Dheda K, Duncan Cja, Emary Krw, Ewer Kj, Fairlie L, Faust Sn, Feng S, Ferreira Dm, Finn A, Goodman Al, Green Cm, Green Ca, Heath Pt, Hill C, Hill H, Hirsch I, Hodgson Shc, Izu A, Jackson S, Jenkin D, Joe Ccd, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie Am, Lelliott A, Libri V, Lillie Pj, Mallory R, Mendes Ava, Milan Ep, Minassian Am, Mcgregor A, Morrison H, Mujadidi Yf, Nana A, Oâ€™reilly Pj, Padayachee Sd, Pittella A, Plested E, Pollock Km, Ramasamy Mn, Rhead S, Schwarzbold Av, Singh N, Smith A, Song R, Snape Md, Sprinz E, Sutherland Rk, Tarrant R, Thomson Ec, TÃ¶rÃ¶k Me, Toshner M, Turner Dpj, Vekemans J, Villafana Tl, Watson Mee, Williams Cj, Douglas Ad, Hill Avs, Lambe T, Gilbert Sc, Pollard Aj; Oxford Covid Vaccine Trial Group. Safety And Efficacy Of The Chadox1 Ncov-19 Vaccine (Azd1222) Against Sars-Cov-2: An Interim Analysis Of Four Randomised Controlled Trials In Brazil, South Africa, And The Uk. Lancet. 2021 Jan;397(10269):99-111. [Pubmed] [Google Scholar]

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre Ch, Nguyen Lh, Drew Da, Merino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas Ls, Molteni E, Graham Ms, Modat M, Joshi Ad, Mangino M, Hammers A, Goodman Al, Chan At, Wolf J, Steves Cj, Valdes Am, Ourselin S, Spector Td. Vaccine Side-Effects And Sars-Cov-2 Infection After Vaccination In Users Of The Covid Symptom Study App In The Uk: A Prospective Observational Study. Lancet Infect Dis. 2021 Jul;21(7):939-49. [Pubmed] [Google Scholar]

Seruminstitute.com [Internet]. Covishield Factsheet. Available From: Https://Www.seruminstitute.com/Pdf/Covishield_fact_sheet.pdf

Bharatbiotech.com [Internet]. Covaxin Factsheet. Available From: Https://Www.bharatbiotech.com/Images/Covaxin/Covaxin-Fact-Sheet.pdf

Jeon M, Kim J, Oh Ce, Lee Jy. Adverse Events Following Immunization Associated With The First And Second Doses Of The Chadox1 Ncov-19 Vaccine Among Healthcare Workers In Korea. Vaccines. 2021 Oct;9(10):1096. [Pubmed] [Google Scholar]

Inbaraj Lr, George Ce, Franklyn Nn. How Safe Is Covishield (Chadox1ncov-19) Vaccine? Experience From A Tertiary Care Hospital In South India. Curr Med Iss. 2021;19(3):162-4. [Google Scholar]

HervÃ© C, LaupÃ¨ze B, Del Giudice G, Didierlaurent Am, Da Silva Ft. The Howâ€™s And Whatâ€™s Of Vaccine Reactogenicity. Npj Vaccines. 2019 Sep;4(1):1. [Pubmed] [Google Scholar]